Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Histopathological growth patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy.

Höppener DJ, Nierop PMH, Herpel E, Rahbari NN, Doukas M, Vermeulen PB, Grünhagen DJ, Verhoef C.

Clin Exp Metastasis. 2019 Aug;36(4):311-319. doi: 10.1007/s10585-019-09975-0. Epub 2019 May 27.

2.

Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns.

Nierop PMH, Galjart B, Höppener DJ, van der Stok EP, Coebergh van den Braak RRJ, Vermeulen PB, Grünhagen DJ, Verhoef C.

Clin Exp Metastasis. 2019 Apr;36(2):109-118. doi: 10.1007/s10585-019-09960-7. Epub 2019 Mar 6.

3.

Vessel co-option in cancer.

Kuczynski EA, Vermeulen PB, Pezzella F, Kerbel RS, Reynolds AR.

Nat Rev Clin Oncol. 2019 Aug;16(8):469-493. doi: 10.1038/s41571-019-0181-9. Review.

PMID:
30816337
4.

Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases.

Galjart B, Nierop PMH, van der Stok EP, van den Braak RRJC, Höppener DJ, Daelemans S, Dirix LY, Verhoef C, Vermeulen PB, Grünhagen DJ.

Angiogenesis. 2019 May;22(2):355-368. doi: 10.1007/s10456-019-09661-5. Epub 2019 Jan 12.

5.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 Aug;21(3):425-532. doi: 10.1007/s10456-018-9613-x. Review.

6.

Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies.

Lazaris A, Amri A, Petrillo SK, Zoroquiain P, Ibrahim N, Salman A, Gao ZH, Vermeulen PB, Metrakos P.

J Pathol Clin Res. 2018 Jul;4(3):184-192. doi: 10.1002/cjp2.100. Epub 2018 Apr 14.

7.

Non-angiogenic tumours and their influence on cancer biology.

Donnem T, Reynolds AR, Kuczynski EA, Gatter K, Vermeulen PB, Kerbel RS, Harris AL, Pezzella F.

Nat Rev Cancer. 2018 May;18(5):323-336. doi: 10.1038/nrc.2018.14. Epub 2018 Mar 9. Review.

PMID:
29520090
8.

Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy.

van Dam PJ, Daelemans S, Ross E, Waumans Y, Van Laere S, Latacz E, Van Steen R, De Pooter C, Kockx M, Dirix L, Vermeulen PB.

Semin Cancer Biol. 2018 Oct;52(Pt 2):86-93. doi: 10.1016/j.semcancer.2018.01.009. Epub 2018 Jan 31. Review.

PMID:
29355613
9.

XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.

Evans MK, Brown MC, Geradts J, Bao X, Robinson TJ, Jolly MK, Vermeulen PB, Palmer GM, Gromeier M, Levine H, Morse MA, Van Laere SJ, Devi GR.

Cancer Res. 2018 Apr 1;78(7):1726-1738. doi: 10.1158/0008-5472.CAN-17-1667. Epub 2018 Jan 19.

10.

International consensus guidelines for scoring the histopathological growth patterns of liver metastasis.

van Dam PJ, van der Stok EP, Teuwen LA, Van den Eynden GG, Illemann M, Frentzas S, Majeed AW, Eefsen RL, Coebergh van den Braak RRJ, Lazaris A, Fernandez MC, Galjart B, Laerum OD, Rayes R, Grünhagen DJ, Van de Paer M, Sucaet Y, Mudhar HS, Schvimer M, Nyström H, Kockx M, Bird NC, Vidal-Vanaclocha F, Metrakos P, Simoneau E, Verhoef C, Dirix LY, Van Laere S, Gao ZH, Brodt P, Reynolds AR, Vermeulen PB.

Br J Cancer. 2017 Nov 7;117(10):1427-1441. doi: 10.1038/bjc.2017.334. Epub 2017 Oct 5.

11.

Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).

Joglekar-Javadekar M, Van Laere S, Bourne M, Moalwi M, Finetti P, Vermeulen PB, Birnbaum D, Dirix LY, Ueno N, Carter M, Rains J, Ramachandran A, Bertucci F, van Golen KL.

Neoplasia. 2017 Jul;19(7):564-573. doi: 10.1016/j.neo.2017.03.002. Epub 2017 Jun 10.

12.

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.

Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR.

J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845. Epub 2016 Dec 29.

13.

Assessment of pathological response to therapy using lipid mass spectrometry imaging.

Patterson NH, Alabdulkarim B, Lazaris A, Thomas A, Marcinkiewicz MM, Gao ZH, Vermeulen PB, Chaurand P, Metrakos P.

Sci Rep. 2016 Nov 14;6:36814. doi: 10.1038/srep36814.

14.

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.

Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Nathan M, Wotherspoon A, Gao ZH, Shi Y, Van den Eynden G, Daley F, Peckitt C, Tan X, Salman A, Lazaris A, Gazinska P, Berg TJ, Eltahir Z, Ritsma L, Van Rheenen J, Khashper A, Brown G, Nystrom H, Sund M, Van Laere S, Loyer E, Dirix L, Cunningham D, Metrakos P, Reynolds AR.

Nat Med. 2016 Nov;22(11):1294-1302. doi: 10.1038/nm.4197. Epub 2016 Oct 17.

15.

mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy.

van der Stok EP, Smid M, Sieuwerts AM, Vermeulen PB, Sleijfer S, Ayez N, Grünhagen DJ, Martens JW, Verhoef C.

Mol Oncol. 2016 Dec;10(10):1542-1550. doi: 10.1016/j.molonc.2016.09.002. Epub 2016 Sep 20.

16.

Development and Validation of a Histological Method to Measure Microvessel Density in Whole-Slide Images of Cancer Tissue.

Marien KM, Croons V, Waumans Y, Sluydts E, De Schepper S, Andries L, Waelput W, Fransen E, Vermeulen PB, Kockx MM, De Meyer GR.

PLoS One. 2016 Sep 1;11(9):e0161496. doi: 10.1371/journal.pone.0161496. eCollection 2016.

17.

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.

Kuczynski EA, Yin M, Bar-Zion A, Lee CR, Butz H, Man S, Daley F, Vermeulen PB, Yousef GM, Foster FS, Reynolds AR, Kerbel RS.

J Natl Cancer Inst. 2016 Apr 8;108(8). doi: 10.1093/jnci/djw030. Print 2016 Aug.

18.

The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis.

Clarke CJ, Berg TJ, Birch J, Ennis D, Mitchell L, Cloix C, Campbell A, Sumpton D, Nixon C, Campbell K, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Jones JL, Haywood L, Pulleine E, Yin H, Strathdee D, Sansom O, Blyth K, McNeish I, Zanivan S, Reynolds AR, Norman JC.

Curr Biol. 2016 Mar 21;26(6):755-65. doi: 10.1016/j.cub.2016.01.045. Epub 2016 Mar 3.

19.

Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma.

Pastushenko I, Van den Eynden GG, Vicente-Arregui S, Prieto-Torres L, Alvarez-Alegret R, Querol I, Dirix LY, Carapeto FJ, Vermeulen PB, Van Laere SJ.

Am J Dermatopathol. 2016 May;38(5):338-46. doi: 10.1097/DAD.0000000000000488.

PMID:
26909582
20.

Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.

Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Frentzas S, Vermeulen PB, Preece N, Springer CJ, Powles T, Nathan PD, Larkin J, Gore M, Vasudev NS, Reynolds AR.

Mol Cancer Ther. 2016 Jan;15(1):172-83. doi: 10.1158/1535-7163.MCT-15-0170. Epub 2015 Oct 20.

21.

Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.

Eefsen RL, Engelholm L, Alpizar-Alpizar W, Van den Eynden GG, Vermeulen PB, Christensen IJ, Laerum OD, Rolff HC, Høyer-Hansen G, Vainer B, Osterlind K, Illemann M.

Cancer Microenviron. 2015 Aug;8(2):93-100. doi: 10.1007/s12307-015-0172-z. Epub 2015 Aug 14.

22.

Peritumoral D2-40 Chalkley score independently predicts metastases and survival in patients with cutaneous malignant melanoma.

Pastushenko I, Vermeulen PB, Vicente-Arregui S, Van den Eynden GG, Alvarez-Alegret R, Querol I, Rutten A, Carapeto FJ, Dirix LY, Van Laere S.

J Cutan Pathol. 2015 Oct;42(10):699-711. doi: 10.1111/cup.12571. Epub 2015 Sep 11.

PMID:
26264662
23.

Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.

van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ.

Breast Cancer Res. 2015 Feb 18;17:21. doi: 10.1186/s13058-015-0526-y. Review.

24.

Growth pattern of colorectal liver metastasis as a marker of recurrence risk.

Eefsen RL, Vermeulen PB, Christensen IJ, Laerum OD, Mogensen MB, Rolff HC, Van den Eynden GG, Høyer-Hansen G, Osterlind K, Vainer B, Illemann M.

Clin Exp Metastasis. 2015 Apr;32(4):369-81. doi: 10.1007/s10585-015-9715-4. Epub 2015 Mar 31.

PMID:
25822899
25.

Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K, Finetti P, Bertucci F, Timmermans MM, van Deurzen CH, Martens JW, Simon I, Roepman P, Linn SC, van Dam P, Kok M, Lardon F, Vermeulen PB, Foekens JA, Dirix L, Berns EM, Van Laere S.

Mol Oncol. 2015 Jun;9(6):1218-33. doi: 10.1016/j.molonc.2015.02.006. Epub 2015 Mar 4.

26.

Melanomas arising on skin with chronic sun-induced damage exhibit low degree of angiogenesis and lymphangiogenesis.

Pastushenko I, Vicente-Arregui S, Van den Eynden GG, Gracia-Cazaña T, Carapeto FJ, Alvarez-Alegret R, Dirix LY, Vermeulen PB, Van Laere S.

Am J Dermatopathol. 2015 Jun;37(6):451-4. doi: 10.1097/DAD.0000000000000265.

PMID:
25747811
27.

Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer.

Peeters DJ, Brouwer A, Van den Eynden GG, Rutten A, Onstenk W, Sieuwerts AM, Van Laere SJ, Huget P, Pauwels P, Peeters M, Vermeulen PB, Dirix LY.

Cancer Lett. 2015 Jan 28;356(2 Pt B):872-9. doi: 10.1016/j.canlet.2014.10.039. Epub 2014 Nov 4.

PMID:
25449778
28.

Mechanism of tumour vascularization in experimental lung metastases.

Szabo V, Bugyik E, Dezso K, Ecker N, Nagy P, Timar J, Tovari J, Laszlo V, Bridgeman VL, Wan E, Frentzas S, Vermeulen PB, Reynolds AR, Dome B, Paku S.

J Pathol. 2015 Feb;235(3):384-96. doi: 10.1002/path.4464. Epub 2014 Dec 18.

PMID:
25319725
29.

Tumor stromal phenotypes define VEGF sensitivity--letter.

Van den Eynden GG, Bird NC, Dirix LY, Eefsen RL, Gao ZH, Høyer-Hansen G, Illemann M, Majeed AW, Metrakos P, Reynolds AR, Vainer B, van Dam PJ, Van Laere SJ, Vermeulen PB, Vidal-Vanaclocha F, Brodt P; Liver Metastasis Research Network.

Clin Cancer Res. 2014 Oct 1;20(19):5140. doi: 10.1158/1078-0432.CCR-14-0158. No abstract available.

30.

Squamous cell carcinomas of the skin explore angiogenesis-independent mechanisms of tumour vascularization.

Pastushenko I, Gracia-Cazaña T, Vicente-Arregui S, Van den Eynden GG, Ara M, Vermeulen PB, Carapeto FJ, Van Laere SJ.

J Skin Cancer. 2014;2014:651501. doi: 10.1155/2014/651501. Epub 2014 May 6.

31.

Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.

Pastushenko I, Vermeulen PB, Van den Eynden GG, Rutten A, Carapeto FJ, Dirix LY, Van Laere S.

Br J Dermatol. 2014 Aug;171(2):220-33. doi: 10.1111/bjd.12973. Epub 2014 Jul 26. Review.

PMID:
24641095
32.

A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples.

Marsan M, Van den Eynden G, Limame R, Neven P, Hauspy J, Van Dam PA, Vergote I, Dirix LY, Vermeulen PB, Van Laere SJ.

PLoS One. 2014 Feb 21;9(2):e89262. doi: 10.1371/journal.pone.0089262. eCollection 2014.

33.

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.

Peeters DJ, van Dam PJ, Van den Eynden GG, Rutten A, Wuyts H, Pouillon L, Peeters M, Pauwels P, Van Laere SJ, van Dam PA, Vermeulen PB, Dirix LY.

Br J Cancer. 2014 Jan 21;110(2):375-83. doi: 10.1038/bjc.2013.743. Epub 2013 Dec 24.

34.

Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: systematic review and meta-analysis.

Pastushenko I, Vermeulen PB, Carapeto FJ, Van den Eynden G, Rutten A, Ara M, Dirix LY, Van Laere S.

Br J Dermatol. 2014 Jan;170(1):66-77. doi: 10.1111/bjd.12688. Review.

PMID:
24134623
35.

The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications.

Van den Eynden GG, Majeed AW, Illemann M, Vermeulen PB, Bird NC, Høyer-Hansen G, Eefsen RL, Reynolds AR, Brodt P.

Cancer Res. 2013 Apr 1;73(7):2031-43. doi: 10.1158/0008-5472.CAN-12-3931. Epub 2013 Mar 27. Review.

36.

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting.

Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothé F, Ignatiadis M, Sieuwerts AM, Lambrechts D, Rutten A, van Dam PA, Pauwels P, Peeters M, Vermeulen PB, Dirix LY.

Br J Cancer. 2013 Apr 2;108(6):1358-67. doi: 10.1038/bjc.2013.92. Epub 2013 Mar 7.

37.

The interaction between ER and NFκB in resistance to endocrine therapy.

Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, Dirix LY, Van Laere SJ.

Breast Cancer Res. 2012 Aug 31;14(4):212. doi: 10.1186/bcr3196. Review.

38.

Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases.

Eefsen RL, Van den Eynden GG, Høyer-Hansen G, Brodt P, Laerum OD, Vermeulen PB, Christensen IJ, Wettergren A, Federspiel B, Willemoe GL, Vainer B, Osterlind K, Illemann M.

J Oncol. 2012;2012:907971. doi: 10.1155/2012/907971. Epub 2012 Aug 2.

39.

Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase.

Lehman HL, Van Laere SJ, van Golen CM, Vermeulen PB, Dirix LY, van Golen KL.

Mol Cancer Res. 2012 Oct;10(10):1306-18. doi: 10.1158/1541-7786.MCR-12-0173. Epub 2012 Aug 15.

40.

The histological growth pattern of colorectal cancer liver metastases has prognostic value.

Van den Eynden GG, Bird NC, Majeed AW, Van Laere S, Dirix LY, Vermeulen PB.

Clin Exp Metastasis. 2012 Aug;29(6):541-9. doi: 10.1007/s10585-012-9469-1. Epub 2012 Apr 3.

PMID:
22476470
41.

Inflammatory HER2-positive breast cancer.

Dirix LY, Vermeulen PB.

Lancet Oncol. 2012 Apr;13(4):324-6. doi: 10.1016/S1470-2045(12)70081-5. Epub 2012 Feb 28. No abstract available.

PMID:
22377127
42.

Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers.

van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ.

Breast Cancer Res. 2012 Feb 21;14(1):R34.

43.

A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.

Trinh XB, Sas L, Van Laere SJ, Prové A, Deleu I, Rasschaert M, Van de Velde H, Vinken P, Vermeulen PB, Van Dam PA, Wojtasik A, De Mesmaeker P, Tjalma WA, Dirix LY.

Oncol Rep. 2012 Mar;27(3):657-63. doi: 10.3892/or.2011.1562. Epub 2011 Nov 24.

PMID:
22134540
44.

VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer.

Trinh XB, van Dam PA, Vermeulen PB, Van Laere SJ, Van den Eynden GG, Tjalma WA, Dirix LY.

Clin Transl Oncol. 2011 Nov;13(11):805-8. doi: 10.1007/s12094-011-0737-3.

PMID:
22082645
45.

Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.

Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, Bachvarov D, Plante M, Berns EM, Helleman J, Van Laere SJ, van Dam PA.

PLoS One. 2011;6(7):e22469. doi: 10.1371/journal.pone.0022469. Epub 2011 Jul 25.

46.

Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?

Dirix LY, Van Dam PA, Prove AM, Vermeulen PB.

Ther Adv Med Oncol. 2010 Sep;2(5):331-42. doi: 10.1177/1758834010376301.

47.

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer.

Peeters DJ, Van den Eynden GG, van Dam PJ, Prové A, Benoy IH, van Dam PA, Vermeulen PB, Pauwels P, Peeters M, Van Laere SJ, Dirix LY.

Br J Cancer. 2011 Apr 26;104(9):1472-7. doi: 10.1038/bjc.2011.122. Epub 2011 Apr 5.

48.

Array-based DNA methylation profiling for breast cancer subtype discrimination.

Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, Pauwels P, Vermeulen PB, Dirix LY, Van Laere SJ.

PLoS One. 2010 Sep 7;5(9):e12616. doi: 10.1371/journal.pone.0012616.

49.

Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype.

Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, Van Laere SJ.

Br J Cancer. 2010 Aug 10;103(4):532-41. doi: 10.1038/sj.bjc.6605787. Epub 2010 Jul 27.

50.

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M.

Ann Oncol. 2011 Mar;22(3):515-23. doi: 10.1093/annonc/mdq345. Epub 2010 Jul 5.

Supplemental Content

Loading ...
Support Center